Golden State Wealth Management’s Aligos Therapeutics ALGS Stock Holding History

Golden State Wealth Management’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.9K	Hold	2,674	–	–	﹤0.01%	915
2025 Q4	$24.9K	Hold	2,674	–	–	﹤0.01%	875
2025 Q3	$26.2K	Hold	2,674	–	–	﹤0.01%	848
2025 Q2	$19.3K	Hold	2,674	–	–	﹤0.01%	895
2025 Q1	$22.1K	Hold	2,674	–	–	﹤0.01%	779
2024 Q4	$107K	Buy	+2,674	New	+$51.7K	0.02%	417
2022 Q1	$36K	Buy	674 +80	+13%	+$6.41K	0.01%	305
2021 Q4	$176K	Hold	594	–	–	0.03%	356
2021 Q3	$230K	Hold	594	–	–	0.05%	268
2021 Q2	$303K	Hold	594	–	–	0.07%	225
2021 Q1	$337K	Hold	594	–	–	0.11%	133
2020 Q4	$411K	Buy	+594	New	+$289K	0.12%	145

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Golden State Wealth Management's ALGS Position: Q1 2026 in Review

Golden State Wealth Management held its Aligos Therapeutics (ALGS) position steady in Q1 2026 at 2,674 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #915.

Golden State Wealth Management first reported a position in ALGS in Q4 2020 and has held it in 12 quarters since. The position peaked at $411K in Q4 2020. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Golden State Wealth Management held 2,674 shares of Aligos Therapeutics worth $19.9K as of Q1 2026.
Golden State Wealth Management left its Aligos Therapeutics share count unchanged in Q1 2026.
Aligos Therapeutics made up ﹤0.01% of Golden State Wealth Management's portfolio in Q1 2026, its #915 holding.
Golden State Wealth Management first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 12 quarters since.
Golden State Wealth Management's Aligos Therapeutics position peaked at $411K in Q4 2020.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.